STAT

DECEMBER 5, 2023

Damian here with a special thanks to everyone who joined us for STAT’s live event in New York City last night.   Sign up  to get our biotech newsletter in your inbox. Good morning, everyone.

Drug Pricing 246

Drug Pricing Drug Development 246

STAT

DECEMBER 6, 2022

NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s drug lecanemab , according to remarks made by both a critic of other Alzheimer’s medicines and the CEO of the company that developed it.

Drug Pricing 246

Drug Pricing Drug Development 246

STAT

SEPTEMBER 24, 2024

The researchers did not see any severe adverse events linked to the drug, and there were no treatment-related discontinuations. The biotech plans to start a Phase 2b trial of the drug, called MET-097, in the fourth quarter of this year, with data expected in the first half of next year.

Drug Pricing 304

Drug Pricing Drug Development 304

Safe Biologics

SEPTEMBER 12, 2023

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

NOVEMBER 12, 2023

The event will convene patients, providers, policymakers and advocates to discuss a number of topics impacting the health care space and will be held at the Mayflower Hotel in Washington D.C. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Pharmaceutical Technology

JUNE 6, 2025

wants to ensure the ensuing the US does not lag behind other countries in drug development. We want to make sure we are getting rid of the regulatory impediments [that stop drugs getting to market],” RFK Jr stated. Tasos Katopodis / Stringer via Getty Images.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Communication Hospitals Drug Development 52

Safe Biologics

DECEMBER 6, 2023

Learn about ASBM’s recent educational activities surrounding IRA Medicare drug price negotiation, interchangeable biosimilars, and other key policy issues affecting patient access to medicines. ASBM to Exhibit at ACR Convergence 2023 Visit ASBM at Booth #2612 at ACR Convergence in San Diego, CA, November 12-14th. Read it here.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

Pharmaceutical Technology

JUNE 29, 2022

This year has already been eventful when it comes to the development of therapies for rare diseases. Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 98

STAT

NOVEMBER 21, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at an ambitious genomics startup, some cautious optimism on Wall Street, and a rough day for an American in Germany. Read the rest…

Drug Pricing 245

Drug Pricing Drug Development Vaccines 245

STAT

AUGUST 24, 2023

  A new analysis of mid-year price hikes has found that, despite policy changes under the Inflation Reduction Act, drug prices are on the rise , STAT reports.

Drug Pricing 246

Drug Pricing Pharmaceutical Manufacturing Drug Development 246

Safe Biologics

OCTOBER 10, 2023

ASBM Statement on Announcement of Medicare Drug Price-Setting List On August 29th, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed into law last year.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Pharmaceutical Technology

DECEMBER 27, 2022

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight.

Vaccines 122

Vaccines Drug Development Drug Pricing 122

Safe Biologics

SEPTEMBER 11, 2023

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. 1] 90% of new cancer drugs are available in the U.S.

Drug Pricing 150

Drug Pricing Biosimilars Drug Development Vaccines 150

STAT

DECEMBER 6, 2024

Some more good news: Next week will bring a great STAT virtual event on the next frontier in clinical trials.   Sign up  to get our biotech newsletter in your inbox. Somehow, some way, we made it to Friday. Congratulations to all. Read details and register here. Read the rest…

Drug Pricing 256

Drug Pricing Drug Development 256

STAT

MAY 30, 2025

We’ll be delivering this newsletter, reporting stories, and hosting STAT events over the next four days. Reporters Matt Herper, Adam Feuerstein, and Angus Chen are in Chicago — laptops open, cellphones charged. Read the rest…

Drug Pricing 218

Drug Pricing Drug Development 218

STAT

JANUARY 6, 2025

Today, we have a new biotech scorecard, which lays out the next quarter’s worth of the sector’s expected stock-moving events.   Sign up  to get our biotech newsletter in your inbox. Also, we see the Trump administration’s transition at the FDA taking shape, and more. Read the rest…

Compounding 310

Compounding Drug Pricing Drug Development 310

STAT

NOVEMBER 12, 2024

My colleagues are hosting a virtual event on LinkedIn today (at 1 pm ET) about how President-elect Trump’s administration could transform health care and biotech.   Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.    Good morning.

Drug Pricing 279

Drug Pricing Drug Development 279

BioPharma Dive

JUNE 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? You can unsubscribe at anytime. Its new CEO has to figure out what’s next.

Diabetes 57

Diabetes Drug Pricing Drug Development Compounding 57

BioPharma Dive

JUNE 5, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

Drug Pricing 52

Drug Pricing Drug Development Vaccines Pharmaceutical Manufacturing 52

BioPharma Dive

JUNE 11, 2025

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. You can unsubscribe at anytime. Sanofi’s $9.1 Sanofi’s $9.1 © 2025 TechTarget, Inc. or its subsidiaries. All rights reserved.

Drug Pricing 67

Drug Pricing Immunity Immunization Drug Development 67

Safe Biologics

MARCH 10, 2025

This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. What Will 2025 Mean for Medicare Drug Price Setting Under the IRA?

Biosimilars 130

Biosimilars Independent Pharmacies Drug Pricing Vaccines 130